Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment
Objective: Multiple myeloma (MM) has a better survival outcome because of the development of drugs. However, equivalent outcomes cannot be expected from the same drug. Therefore, how the treatment schedule is managed is important. We analyzed VMP (bortezomib, melphalan, and prednisolone) data to det...
Main Authors: | Su-Hee Cho, Ho-jin Shin, Ki Sun Jung, Do Young Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Publishing House
2019-05-01
|
Series: | Turkish Journal of Hematology |
Subjects: | |
Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-78045 |
Similar Items
-
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
by: Se Ryeon Lee, et al.
Published: (2019-11-01) -
Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
by: Taleb Azarm, et al.
Published: (2012-01-01) -
The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
by: Jeng-Shiun Du, et al.
Published: (2022-01-01) -
Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01) -
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
by: Morabito F, et al.
Published: (2021-07-01)